Sexual hormone and traditional Chinese patent medicine for early postmenopausal women:effect on quality of life and cost-utility analysis
10.3321/j.issn:1673-4254.2009.11.027
- VernacularTitle:性激素与中成药治疗对绝经早期妇女生存质量的影响及其成本效用分析
- Author:
Ling-Ling ZHOU
1
;
Liang-Zhi XU
;
Hong-Wei LIU
;
Jing ZHANG
;
Ying LIU
;
Xiao-Fang LIU
;
Liu-Lin TANG
;
Jing ZHUANG
;
Xiao-Xian LIU
;
Lin QIAO
Author Information
1. 四川大学华西第二医院
- Keywords:
early postmenopause;
Premarin;
Kuntai capsule;
quality-of-life;
cost-utility analysis
- From:
Journal of Southern Medical University
2009;29(11):2182-2186
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of Premarin and Kuntai capsule (a traditional Chinese patent medicine) on the quality of life (QOL) and their cost-utility in early postmenopausal women. Methods Fifty-seven women with menopausal syndrome in the early postmenopausal stage were randomly allocated into Premarin group (0.3 mg/day and 0.6 mg/day alternately, n=29) and Kuntai group (4 g/day, n=28). The therapies lasted for one year and the patients were followed up every 3 months. The QOL of the patients was evaluated and the utility scores were obtained from rating scale to conduct a cost-utility analysis (CUA). Results At each follow-up examination, no significant difference was found in the QOL between the two groups (P>0.05). The QOL obviously increased after the 1-year-long therapy in both the groups, and Kuntai required longer treatment time than Premarin to take effect. The cost-utility ratio of Premarin and Kuntai were 13581.45 yuan/QALY (quality adjusted life year) and 25105.12 yuan/QALY, respectively. Both incremental cost analysis and sensitivity analysis showed that Kuntai was more costly than Premarin. The result of per-protocol analysis was consistent with that of intention-to-treat analysis. Conclusion At early stage of menopause, the QOL of women with menopausal syndrome can be significantly improved by low-dose Premarin and Kuntai capsule, but the latter is more costly.
